David Turkaly
Stock Analyst at Citizens
(2.20)
# 2,827
Out of 5,148 analysts
148
Total ratings
41.18%
Success rate
-3.96%
Average return
Main Sectors:
Stocks Rated by David Turkaly
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LNTH Lantheus Holdings | Maintains: Market Outperform | $78 → $85 | $76.30 | +11.40% | 11 | Feb 27, 2026 | |
| AXGN Axogen | Maintains: Market Outperform | $34 → $42 | $30.65 | +37.03% | 9 | Feb 24, 2026 | |
| MDXG MiMedx Group | Initiates: Market Outperform | $10 | $4.88 | +104.92% | 1 | Feb 23, 2026 | |
| SYK Stryker | Upgrades: Market Outperform | $440 | $387.02 | +13.69% | 4 | Dec 19, 2025 | |
| TELA TELA Bio | Maintains: Market Outperform | $7 → $5 | $0.86 | +480.92% | 7 | Nov 14, 2025 | |
| APYX Apyx Medical | Upgrades: Market Outperform | $8 | $3.28 | +143.90% | 6 | Nov 12, 2025 | |
| KIDS OrthoPediatrics | Maintains: Market Outperform | $35 → $25 | $19.22 | +30.07% | 12 | Oct 10, 2025 | |
| OFIX Orthofix Medical | Reiterates: Market Perform | n/a | $13.37 | - | 2 | Jun 6, 2025 | |
| GMED Globus Medical | Reiterates: Market Perform | n/a | $93.80 | - | 3 | May 27, 2025 | |
| HAE Haemonetics | Reiterates: Market Outperform | $100 | $63.88 | +56.54% | 12 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $265 → $280 | $247.77 | +13.01% | 18 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $35 → $25 | $10.43 | +139.69% | 15 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $62 → $55 | $25.70 | +114.01% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $140 → $125 | $99.49 | +25.64% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $400 → $500 | $384.86 | +29.92% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $122.93 | - | 15 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $32 | $15.70 | +103.82% | 7 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $16 | $5.26 | +204.18% | 1 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $3 | $1.29 | +132.56% | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $7.51 | -33.42% | 1 | Oct 6, 2017 |
Lantheus Holdings
Feb 27, 2026
Maintains: Market Outperform
Price Target: $78 → $85
Current: $76.30
Upside: +11.40%
Axogen
Feb 24, 2026
Maintains: Market Outperform
Price Target: $34 → $42
Current: $30.65
Upside: +37.03%
MiMedx Group
Feb 23, 2026
Initiates: Market Outperform
Price Target: $10
Current: $4.88
Upside: +104.92%
Stryker
Dec 19, 2025
Upgrades: Market Outperform
Price Target: $440
Current: $387.02
Upside: +13.69%
TELA Bio
Nov 14, 2025
Maintains: Market Outperform
Price Target: $7 → $5
Current: $0.86
Upside: +480.92%
Apyx Medical
Nov 12, 2025
Upgrades: Market Outperform
Price Target: $8
Current: $3.28
Upside: +143.90%
OrthoPediatrics
Oct 10, 2025
Maintains: Market Outperform
Price Target: $35 → $25
Current: $19.22
Upside: +30.07%
Orthofix Medical
Jun 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $13.37
Upside: -
Globus Medical
May 27, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $93.80
Upside: -
Haemonetics
May 20, 2025
Reiterates: Market Outperform
Price Target: $100
Current: $63.88
Upside: +56.54%
May 16, 2025
Maintains: Market Outperform
Price Target: $265 → $280
Current: $247.77
Upside: +13.01%
May 9, 2025
Maintains: Market Outperform
Price Target: $35 → $25
Current: $10.43
Upside: +139.69%
May 9, 2025
Maintains: Market Outperform
Price Target: $62 → $55
Current: $25.70
Upside: +114.01%
May 7, 2025
Maintains: Market Outperform
Price Target: $140 → $125
Current: $99.49
Upside: +25.64%
May 5, 2025
Maintains: Market Outperform
Price Target: $400 → $500
Current: $384.86
Upside: +29.92%
Apr 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $122.93
Upside: -
Feb 25, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $15.70
Upside: +103.82%
Jan 29, 2025
Reiterates: Market Outperform
Price Target: $16
Current: $5.26
Upside: +204.18%
Aug 14, 2024
Maintains: Market Outperform
Price Target: $7 → $3
Current: $1.29
Upside: +132.56%
Oct 6, 2017
Initiates: Outperform
Price Target: $5
Current: $7.51
Upside: -33.42%